Atrial Fibrillation and Thromboembolism in Patients With Chronic Kidney Disease

Journal of the American College of Cardiology

Volumn 68, Issue 13, 2016, Pages 1452-1464

  Lau, Yee C ^a   Proietti, Marco ^a   Guiducci, Elisa ^a,b   Blann, Andrew D ^a   Lip, Gregory Y H ^a,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c AALBORG UNIVERSITY   (Denmark)

Author keywords

anticoagulation; bleeding risk; stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN III; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; CYCLIC AMP; D DIMER; DABIGATRAN; EDOXABAN; ENDOTHELIN; FIBRINOGEN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROLACTIN; RIVAROXABAN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; WARFARIN; VITAMIN K GROUP;

ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; HEMODYNAMIC PARAMETERS; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; RENAL REPLACEMENT THERAPY; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; UPREGULATION; ALGORITHM; ANTAGONISTS AND INHIBITORS; COMPLICATION; HEMORRHAGE; ORAL DRUG ADMINISTRATION; RENAL INSUFFICIENCY, CHRONIC; STROKE;

ADMINISTRATION, ORAL; ALGORITHMS; ANTICOAGULANTS; ATRIAL FIBRILLATION; HEMORRHAGE; HUMANS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM; VITAMIN K;

EID: 84990937850     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.06.057     Document Type: Review

References (140)

1. 1 Levey, A.S., Eckardt, K.U., Tsukamoto, Y., et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67 (2005), 2089–2100.
2. 2 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3 (2013), 1–150.
3. 3 Jha, V., Garcia-Garcia, G., Iseki, K., et al. Chronic kidney disease: global dimension and perspectives. Lancet 382 (2013), 260–272.
4. 4 Coresh, J., Byrd-Holt, D., Astor, B.C., et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol 16 (2005), 180–188.
5. 5 Heeringa, J., van der Kuip, D.A., Hofman, A., et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 27 (2006), 949–953.
6. 6 Alonso, A., Bengtson, L.G., A rising tide: the global epidemic of atrial fibrillation. Circulation 129 (2014), 829–830.
7. 7 Tsagalis, G., Bakirtzi, N., Manios, E., et al. Atrial fibrillation in chronic hemodialysis patients: prevalence, types, predictors, and treatment practices in Greece. Artif Organs 35 (2011), 916–922.
8. 8 Soliman, E.Z., Prineas, R.J., Go, A.S., et al., Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 159 (2010), 1102–1107.
9. 9 Alonso, A., Lopez, F.L., Matsushita, K., et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 123 (2011), 2946–2953.
10. 10 Ohyama, Y., Imai, M., Kurabayashi, M., Estimated glomerular filtration rate and proteinuria are separately and independently associated with the prevalence of atrial fibrillation in general population. PloS One, 8, 2013, e79717.
11. 11 Suzuki, S., Sagara, K., Otsuka, T., et al. Estimated glomerular filtration rate and proteinuria are associated with persistent form of atrial fibrillation: analysis in Japanese patients. J Cardiol 61 (2013), 53–57.
12. 12 Horio, T., Iwashima, Y., Kamide, K., et al. Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients. J Hypertens 28 (2010), 1738–1744.
13. 13 Baber, U., Howard, V.J., Halperin, J.L., et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol 4 (2011), 26–32.
14. 14 McManus, D.D., Corteville, D.C., Shlipak, M.G., et al. Relation of kidney function and albuminuria with atrial fibrillation (from the Heart and Soul Study). Am J Cardiol 104 (2009), 1551–1555.
15. 15 Liao, J.N., Chao, T.F., Liu, C.J., et al. Incidence and risk factors for new-onset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy. Kidney Int 87 (2015), 1209–1215.
16. 16 Bansal, N., Fan, D., Hsu, C.Y., et al. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation 127 (2013), 569–574.
17. 17 Bansal, N., Hsu, C.Y., Go, A.S., Intersection of cardiovascular disease and kidney disease: atrial fibrillation. Curr Opin Nephrol Hypertens 23 (2014), 275–282.
18. 18 Guo, Y., Wang, H., Zhao, X., et al. Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation. Int J Cardiol 168 (2013), 4678–4684.
19. 19 Watanabe, H., Watanabe, T., Sasaki, S., et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J 158 (2009), 629–636.
20. 20 Zimmerman, D., Sood, M.M., Rigatto, C., et al. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 27 (2012), 3816–3822.
21. 21 Nelson, S.E., Shroff, G.R., Li, S., et al. Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in Medicare patients. J Am Heart Assoc, 1, 2012, e002097.
22. 22 Hwang, H.S., Park, M.W., Yoon, H.E., et al. Clinical significance of chronic kidney disease and atrial fibrillation on morbidity and mortality in patients with acute myocardial infarction. Am J Nephrol 40 (2014), 345–352.
23. 23 Bansal, N., Fan, D., Hsu, C.Y., et al. Incident atrial fibrillation and risk of death in adults with chronic kidney disease. J Am Heart Assoc, 3, 2014, e001303.
24. 24 Pisters, R., Lane, D.A., Nieuwlaat, R., et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138 (2010), 1093–1100.
25. 25 Lip, G.Y., Nieuwlaat, R., Pisters, R., et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 137 (2010), 263–272.
26. 26 Nielsen, P.B., Lane, D.A., Rasmussen, L.H., et al. Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin Res Cardiol 104 (2015), 418–429.
27. 27 Marinigh, R., Lane, D.A., Lip, G.Y., Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 57 (2011), 1339–1348.
28. 28 Watson, T., Shantsila, E., Lip, G.Y., Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 373 (2009), 155–166.
29. 29 Maccallum, P.K., Mathur, R., Hull, S.A., et al. Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study. BMJ Open, 3, 2013, e003343.
30. 30 Yagishita, A., Takahashi, Y., Takahashi, A., et al. Relationship between transesophageal echocardiographic features and glomerular filtration rate in patients with persistent atrial fibrillation. Heart Rhythm, 7, 2010, S387.
31. 31 Providência, R., Fernandes, A., Paiva, L., et al. Decreased glomerular filtration rate and markers of left atrial stasis in patients with nonvalvular atrial fibrillation. Cardiology 124 (2013), 3–10.
32. 32 Blacher, J., Guerin, A.P., Pannier, B., et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99 (1999), 2434–2439.
33. 33 Bolton, C.H., Downs, L.G., Victory, J.G., et al. Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant 16 (2001), 1189–1197.
34. 34 Yildiz, A., Oflaz, H., Pusuroglu, H., et al. Left ventricular hypertrophy and endothelial dysfunction in chronic hemodialysis patients. Am J Kidney Dis 41 (2003), 616–623.
35. 35 Wang, M.C., Tsai, W.C., Chen, J.Y., et al. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis 45 (2005), 494–501.
36. 36 Carrero, J.J., Kyriazis, J., Sonmez, A., et al. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol 7 (2012), 207–215.
37. 37 Heintz, B., Schmidt, P., Maurin, N., et al. Endothelin-1 potentiates ADP-induced platelet aggregation in chronic renal failure. Ren Fail 16 (1994), 481–489.
38. 38 Recio-Mayoral, A., Banerjee, D., Streather, C., et al. Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease—a cross-sectional study of predialysis, dialysis and kidney-transplantation patients. Atherosclerosis 216 (2011), 446–451.
39. 39 Shoji, T., Maekawa, K., Emoto, M., et al. Arterial stiffness predicts cardiovascular death independent of arterial thickness in a cohort of hemodialysis patients. Atherosclerosis 210 (2010), 145–149.
40. 40 Nishizawa, Y., Shoji, T., Maekawa, K., et al. Intima-media thickness of carotid artery predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 41 (2003), S76–S79.
41. 41 Shlipak, M.G., Fried, L.F., Crump, C., et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107 (2003), 87–92.
42. 42 Pecoits-Filho, R., Heimbürger, O., Bárány, P., et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 41 (2003), 1212–1218.
43. 43 Keller, C., Katz, R., Cushman, M., et al. Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol, 9, 2008, 9.
44. 44 Landray, M.J., Wheeler, D.C., Lip, G.Y., et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 43 (2004), 244–253.
45. 45 Tanaka, H., Sonoda, M., Kashima, K., et al. Impact of decreased renal function on coagulation and fibrinolysis in patients with non-valvular atrial fibrillation. Circ J 73 (2009), 846–850.
46. 46 Mercier, E., Branger, B., Vecina, F., et al. Tissue factor coagulation pathway and blood cells activation state in renal insufficiency. Hematol J 2 (2001), 18–25.
47. 47 Adams, M.J., Irish, A.B., Watts, G.F., et al. Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function. Thromb Res 123 (2008), 374–380.
48. 48 Costa, E., Rocha, S., Rocha-Pereira, P., et al. Cross-talk between inflammation, coagulation/fibrinolysis and vascular access in hemodialysis patients. J Vasc Access 9 (2008), 248–253.
49. 49 Shen, L., Lu, G., Dong, N., et al. Von Willebrand factor, ADAMTS13 activity, TNF-α and their relationships in patients with chronic kidney disease. Exp Ther Med 3 (2012), 530–534.
50. 50 Yagmur, E., Frank, R.D., Neulen, J., et al. Platelet hyperaggregability is highly prevalent in patients with chronic kidney disease: an underestimated risk indicator of thromboembolic events. Clin Appl Thrombos Hemost 21 (2015), 132–138.
51. 51 Healey, J.S., Morillo, C.A., Connolly, S.J., Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling. Curr Opin Cardiol 20 (2005), 31–37.
52. 52 Gusbeth-Tatomir, P., Covic, A., Causes and consequences of increased arterial stiffness in chronic kidney disease patients. Kidney Blood Press Res 30 (2007), 97–107.
53. 53 Chue, C.D., Townend, J.N., Steeds, R.P., et al. Arterial stiffness in chronic kidney disease: causes and consequences. Heart 96 (2010), 817–823.
54. 54 Fadem, S.Z., Moe, S.M., Management of chronic kidney disease mineral-bone disorder. Adv Chronic Kidney Dis 14 (2007), 44–53.
55. 55 Go, A.S., Fang, M.C., Udaltsova, N., et al., ATRIA Study Investigators. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation 119 (2009), 1363–1369.
56. 56 Olesen, J.B., Lip, G.Y., Kamper, A.L., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 367 (2012), 625–635.
57. 57 Bonde, A.N., Lip, G.Y., Kamper, A.L., et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 64 (2014), 2471–2482.
58. 58 Friberg, L., Benson, L., Lip, G.Y., Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J 36 (2015), 297–306.
59. 59 Akazawa, T., Nishihara, H., Iwata, H., et al. Preoperative plasma brain natriuretic peptide level is an independent predictor of postoperative atrial fibrillation following off-pump coronary artery bypass surgery. J Anesth 22 (2008), 347–353.
60. 60 Chinda, J., Nakagawa, N., Kabara, M., et al. Impact of decreased estimated glomerular filtration rate on Japanese acute stroke and its subtype. Intern Med 51 (2012), 1661–1666.
61. 61 Roldán, V., Marin, F., Fernández, H., et al. Renal impairment in a “real-life” cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol 111 (2013), 1159–1164.
62. 62 Kumai, Y., Kamouchi, M., Hata, J., et al., FSR Investigators. Proteinuria and clinical outcomes after ischemic stroke. Neurology 78 (2012), 1909–1915.
63. 63 Yahalom, G., Schwartz, R., Schwammenthal, Y., et al. Chronic kidney disease and clinical outcome in patients with acute stroke. Stroke 40 (2009), 1296–1303.
64. 64 Shimizu, Y., Maeda, K., Imano, H., et al. Chronic kidney disease and drinking status in relation to risks of stroke and its subtypes: the Circulatory Risk in Communities Study (CIRCS). Stroke 42 (2011), 2531–2537.
65. 65 Bos, M.J., Koudstaal, P.J., Hofman, A., et al. Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam study. Stroke 38 (2007), 3127–3132.
66. 66 Iseki, K., Kinjo, K., Kimura, Y., et al. Evidence for high risk of cerebral hemorrhage in chronic dialysis patients. Kidney Int 44 (1993), 1086–1090.
67. 67 Ovbiagele, B., Wing, J.J., Menon, R.S., et al. Association of chronic kidney disease with cerebral microbleeds in patients with primary intracerebral hemorrhage. Stroke 44 (2013), 2409–2413.
68. 68 Sood, P., Kumar, G., Nanchal, R., et al. Chronic kidney disease and end-stage renal disease predict higher risk of mortality in patients with primary upper gastrointestinal bleeding. Am J Nephrol 35 (2012), 216–224.
69. 69 Kuo, C.C., Kuo, H.W., Lee, I.M., et al. The risk of upper gastrointestinal bleeding in patients treated with hemodialysis: a population-based cohort study. BMC Nephrol, 14, 2013, 15.
70. 70 Luo, J.C., Leu, H.B., Hou, M.C., et al. Nonpeptic ulcer, nonvariceal gastrointestinal bleeding in hemodialysis patients. Am J Med 126 (2013), 264.e25–264.e32.
71. 71 Huang, K.W., Leu, H.B., Luo, J.C., et al. Different peptic ulcer bleeding risk in chronic kidney disease and end-stage renal disease patients receiving different dialysis. Dig Dis Sci 59 (2014), 807–813.
72. 72 Ng, K.P., Edwards, N.C., Lip, G.Y., et al. Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation. Am J Kidney Dis 62 (2013), 615–632.
73. 73 Reinecke, H., Brand, E., Mesters, R., et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 20 (2009), 705–711.
74. 74 Vanhoutte, P.M., Feletou, M., Taddei, S., Endothelium-dependent contractions in hypertension. Br J Pharmacol 144 (2005), 449–458.
75. 75 Authors/Task Force Members, Camm, A.J., Lip, G.Y.H., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 33 (2012), 2719–2747.
76. 76 Olesen, J.B., Lip, G.Y., Hansen, M.L., et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ, 342, 2011, d124.
77. 77 Piccini, J.P., Stevens, S.R., Chang, Y., et al., ROCKET AF Steering Committee and Investigators. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 127 (2013), 224–232.
78. 78 Bautista, J., Bella, A., Chaudhari, A., et al. Advanced chronic kidney disease in non-valvular atrial fibrillation: extending the utility of R2CHADS2 to patients with advanced renal failure. Clin Kidney J 8 (2015), 226–231.
79. 79 Kornej, J., Hindricks, G., Kosiuk, J., et al. Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry. Circ Arrhythm Electrophysiol 6 (2013), 868–874.
80. 80 Abumuaileq, R.R., Abu-Assi, E., López-López, A., et al. Comparison between CHA2DS2-VASc and the new R2CHADS2 and ATRIA scores at predicting thromboembolic event in non-anticoagulated and anticoagulated patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord, 15, 2015, 156.
81. 81 Chao, T.F., Lin, Y.J., Chang, S.L., et al. R2CHADS2 score and thromboembolic events after catheter ablation of atrial fibrillation in comparison with the CHA2DS2-VASc score. Can J Cardiol 30 (2014), 405–412.
82. 82 Roldán, V., Marín, F., Manzano-Fernandez, S., et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?. Thromb Haemost 109 (2013), 956–960.
83. 83 Banerjee, A., Fauchier, L., Vourc'h, P., et al. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley atrial fibrillation project. J Am Coll Cardiol 61 (2013), 2079–2087.
84. 84 Sengupta, N., Feuerstein, J.D., Patwardhan, V.R., et al. The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study. Am J Gastroenterol 110 (2015), 328–335.
85. 85 Staerk, L., Lip, G.Y., Olesen, J.B., et al. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ, 351, 2015, h5876.
86. 86 Khalid, F., Qureshi, W., Qureshi, S., et al. Impact of restarting warfarin therapy in renal disease anticoagulated patients with gastrointestinal hemorrhage. Ren Fail 35 (2013), 1228–1235.
87. 87 Boriani, G., Savelieva, I., Dan, G.A., et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 17 (2015), 1169–1196.
88. 88 Lane, D.A., Aguinaga, L., Blömstrom-Lundqvist, C., et al. Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiologia (SOLEACE). Europace 17 (2015), 1747–1769.
89. 89 Lane, D.A., Lip, G.Y.H., Patient's values and preferences for stroke prevention in atrial fibrillation: Balancing stroke and bleeding risk with oral anticoagulation. Thromb Haemost 111 (2014), 381–383.
90. 90 Potpara, T.S., Lenarczyk, R., Larsen, T.B., et al. Management of atrial fibrillation in patients with chronic kidney disease in Europe. Results of the European Heart Rhythm Association Survey. Europace 17 (2015), 1862–1867.
91. 91 Li, M., Liu, T., Luo, D., et al. Systematic review and meta-analysis of chronic kidney disease as predictor of atrial fibrillation recurrence following catheter ablation. Cardiol J 21 (2014), 89–95.
92. 92 Hayashi, M., Kaneko, S., Shimano, M., et al. Efficacy and safety of radiofrequency catheter ablation for atrial fibrillation in chronic hemodialysis patients. Nephrol Dial Transplant 29 (2014), 160–167.
93. 93 Kornej, J., Hindricks, G., Banerjee, A., et al. Changes in renal function after catheter ablation of atrial fibrillation are associated with CHADS2 and CHA2DS2-VASc scores and arrhythmia recurrences. Heart 101 (2015), 126–131.
94. 94 Williams, E.S., Thompson, V.P., Chiswell, K.E., et al. Rate versus rhythm control and outcomes in patients with atrial fibrillation and chronic kidney disease: data from the GUSTO-III Trial. Cardiol J 20 (2013), 439–446.
95. 95 Abbott, K.C., Trespalacios, F.C., Taylor, A.J., et al. Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality. BMC Nephrol, 4, 2003, 1.
96. 96 Olesen, J.B., Lip, G.Y., Lindhardsen, J., et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost 106 (2011), 739–749.
97. 97 Genovesi, S., Rossi, E., Gallieni, M., et al. Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. Nephrol Dial Transplant 30 (2015), 491–498.
98. 98 Chan, P.H., Huang, D., Yip, P.S., et al. Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis. Europace 18 (2016), 665–671.
99. 99 Findlay, M.D., Thomson, P.C., Fulton, R.L., et al. Risk factors of ischemic stroke and subsequent outcome in patients receiving hemodialysis. Stroke 46 (2015), 2477–2481.
100. 100 Knoll, F., Sturm, G., Lamina, C., et al. Coumarins and survival in incident dialysis patients. Nephrol Dial Transplant 27 (2012), 332–337.
101. 101 Shen, J.I., Montez-Rath, M.E., Lenihan, C.R., et al. Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am J Kidney Dis 66 (2015), 677–688.
102. 102 Chen, J.J., Lin, L.Y., Yang, Y.H., et al. Anti-platelet or anti-coagulant agent for the prevention of ischemic stroke in patients with end-stage renal disease and atrial fibrillation—a nation-wide database analyses. Int J Cardiol 177 (2014), 1008–1011.
103. 103 Wiesholzer, M., Harm, F., Tomasec, G., et al. Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol 21 (2001), 35–39.
104. 104 Chan, K.E., Lazarus, J.M., Thadhani, R., et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 20 (2009), 2223–2233.
105. 105 Wizemann, V., Tong, L., Satayathum, S., et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 77 (2010), 1098–1106.
106. 106 Phelan, P.J., O'Kelly, P., Holian, J., et al. Warfarin use in hemodialysis patients: what is the risk?. Clin Nephrol 75 (2011), 204–211.
107. 107 Winkelmayer, W.C., Liu, J., Setoguchi, S., et al. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 6 (2011), 2662–2668.
108. 108 Sood, M.M., Larkina, M., Thumma, J.R., et al. Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: results from the DOPPS. Kidney Int 84 (2013), 600–608.
109. 109 Shah, M., Avgil Tsadok, M., Jackevicius, C.A., et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 129 (2014), 1196–1203.
110. 110 Wakasugi, M., Kazama, J.J., Tokumoto, A., et al. Association between warfarin use and incidence of ischemic stroke in Japanese hemodialysis patients with chronic sustained atrial fibrillation: a prospective cohort study. Clin Exp Nephrol 18 (2014), 662–669.
111. 111 Lai, H.M., Aronow, W.S., Kalen, P., et al. Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin. Int J Nephrol Renovasc Dis 2 (2009), 33–37.
112. 112 Hart, R.G., Pearce, L.A., Asinger, R.W., et al. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol 6 (2011), 2599–2604.
113. 113 Providência, R., Marijon, E., Boveda, S., et al. Meta-analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation. Am J Cardiol 114 (2014), 646–653.
114. 114 Proietti, M., Lane, D.A., Lip, G.Y.H., Chronic kidney disease, time in therapeutic range and adverse clinical outcomes in anticoagulated patients with non–valvular atrial fibrillation: observations from the SPORTIF Trials. EBioMedicine 8 (2016), 309–316.
115. 115 Koos, R., Krueger, T., Westenfeld, R., et al. Relation of circulating Matrix Gla-Protein and anticoagulation status in patients with aortic valve calcification. Thromb Haemost 101 (2009), 706–713.
116. 116 Luo, G., Ducy, P., McKee, M.D., et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386 (1997), 78–81.
117. 117 Galloway, P.A., El-Damanawi, R., Bardsley, V., et al. Vitamin K antagonists predispose to calciphylaxis in patients with end-stage renal disease. Nephron 129 (2015), 197–201.
118. 118 Hayashi, M., Takamatsu, I., Kanno, Y., et al., Japanese Calciphylaxis Study Group. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant 27 (2012), 1580–1584.
119. 119 Connolly, S.J., Eikelboom, J., Joyner, C., et al., AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 364 (2011), 806–817.
120. 120 Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al., RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
121. 121 Granger, C.B., Alexander, J.H., McMurray, J.J.V., et al., ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
122. 122 Patel, M.R., Mahaffey, K.W., Garg, J., et al., ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
123. 123 Giugliano, R.P., Ruff, C.T., Braunwald, E., et al., ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 (2013), 2093–2104.
124. 124 Hijazi, Z., Hohnloser, S.H., Oldgren, J., et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 129 (2014), 961–970.
125. 125 Fox, K.A., Piccini, J.P., Wojdyla, D., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 32 (2011), 2387–2394.
126. 126 Hohnloser, S.H., Hijazi, Z., Thomas, L., et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 33 (2012), 2821–2830.
127. 127 Proietti, M., Lip, G.Y., Edoxaban in venous thromboembolism and stroke prevention: an appraisal. Vasc Health Risk Manag 12 (2016), 45–51.
128. 128 Huisman, M.V., Lip, G.Y., Diener, H.C., et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 107 (2012), 838–847.
129. 129 Turpie, A.G., Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation. Ther Clin Risk Manag 10 (2014), 197–205.
130. 130 Heidbuchel, H., Verhamme, P., Alings, M., et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15 (2013), 625–651.
131. 131 Manzano-Fernández, S., Andreu-Cayuelas, J.M., Marín, F., et al. Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation. Rev Esp Cardiol (Engl Ed) 68 (2015), 497–504.
132. 132 Eliquis (apixaban) [tablet prescribing information], 2015, Bristol-Meyers Squibb, Princeton, NJ.
133. 133 Savaysa (edoxoban) [prescribing information], 2015, Daiichi Sankyo, Inc., Parsippany, NJ.
134. 134 De Caterina, R., Husted, S., Wallentin, L., et al. Vitamin K antagonists in heart disease: current status and perspectives (section III). Position paper of the ESC Working Group on Thrombosis—Task Force on Anticoagulants in Heart Disease. Thromb Haemost 110 (2013), 1087–1107.
135. 135 Andreu-Cayuelas, J.M., Pastor-Pérez, F.J., Puche, C.M., et al. Impact of variations in kidney function on nonvitamin K oral anticoagulant dosing in patients with atrial fibrillation and recent acute heart failure. Rev Esp Cardiol (Engl Ed) 69 (2016), 134–140.
136. 136 Miyamoto, K., Aiba, T., Arihiro, S., et al. Impact of renal function deterioration on adverse events during anticoagulation therapy using non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Heart Vessels 31 (2016), 1327–1336.
137. 137 Hrafnkelsdóttir, T., Ottosson, P., Gudnason, T., et al. Impaired endothelial release of tissue-type plasminogen activator in patients with chronic kidney disease and hypertension. Hypertension 44 (2004), 300–304.
138. 138 Friberg, L., Rosenqvist, M., Lip, G.Y., Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182,678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study. Eur Heart J 33 (2012), 1500–1510.
139. 139 Chao, T.F., Liu, C.J., Wang, K.L., et al. Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. Heart Rhythm 11 (2014), 1752–1759.
140. 140 Banerjee, A., Fauchier, L., Vourc'h, P., et al. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 145 (2014), 1370–1382.